Humanin Research

by Dr.James Ross 

Disclaimer: All articles and product details provided on this website are intended for educational and informational purposes only. The products listed here are for in-vitro research only. In-vitro studies are conducted outside of living organisms. These products are not intended as medicines or drugs and have not been approved by the FDA to prevent, treat, or cure any medical condition, ailment, or disease. The direct or indirect administration of these substances to humans or animals is unequivocally prohibited under applicable law.

Summary

Peptides are short amino acid chains—essentially small proteins—that deliver powerful biological signals despite their size. The body naturally produces many peptides, functioning as hormones, messengers, and regulators to control cellular activities. Because they act as precise signals, scientists are investigating peptides as highly targeted tools to influence cell behavior.

In neuroscience, peptides have emerged as a promising area of research. They can mimic natural molecules, activate protective pathways, and in some cases, cross the blood–brain barrier more effectively than conventional drugs. For complex conditions such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), peptides may provide new opportunities to intervene in ways that align closely with the brain’s own communication systems.

The urgency is clear. Alzheimer’s affects over 30 million people globally, progressively impairing memory and identity. Parkinson’s, impacting more than 8 million individuals, is largely managed with dopamine replacement to reduce tremors and rigidity. Yet no current treatment halts the ongoing death of neurons in either disease. Peptides offer hope that they might succeed where traditional therapies have failed.

Why Peptides Matter in Neurological Health

Peptides stand out for several key advantages in treating brain disorders:

• Access to the brain: Certain peptides are engineered to cross the blood–brain barrier, a major challenge for many drugs.
• Targeted action: Custom-designed peptides can bind to specific proteins or receptors, allowing precise intervention.
• Biocompatibility: Built from natural amino acids, peptides typically degrade into harmless byproducts, reducing the risk of side effects.
• Multi-faceted effects: Neurodegenerative diseases involve overlapping problems such as protein aggregation, inflammation, and mitochondrial dysfunction. Peptides can often address several of these processes at once.
• Cutting-edge discovery tools: Advances such as CRISPR editing, high-throughput screening, and new delivery systems (like nasal sprays and nanoparticles) are accelerating peptide research.

These qualities make peptides a particularly compelling focus for Alzheimer’s and Parkinson’s, both of which demand therapies capable of acting on multiple disease pathways.

Notable Peptides Under Investigation

Davunetide (NAP)

Davunetide is an 8–amino acid peptide derived from a brain protein that supports neuronal development. It strengthens microtubules—the internal structures neurons use for transport and stability—that are often compromised in tau-related conditions such as Alzheimer’s.

Animal studies show Davunetide improves cognition, and clinical trials in progressive supranuclear palsy suggest possible benefit, particularly in women. Although it has not yet gained approval, its potential role in stabilizing neuronal structures keeps it under investigation.

Humanin and S14G-Humanin

Humanin is a 24–amino acid peptide encoded in mitochondrial DNA and discovered in 2001. It acts as a defense molecule, protecting against oxidative stress, amyloid toxicity, and protein aggregation. A modified version, S14G-Humanin, is significantly more potent.

These peptides activate survival pathways such as PI3K/AKT and enhance insulin sensitivity. Research demonstrates that Humanin improves cognition in aging mice, reduces amyloid and tau pathology in Alzheimer’s, and protects dopamine neurons in Parkinson’s when delivered intranasally.

Exendin-4 and GLP-1 Analogues

Exendin-4, first identified in Gila monster venom, mimics the hormone GLP-1. Its analogues—including exenatide, liraglutide, and semaglutide—are already used for type 2 diabetes. In Alzheimer’s and Parkinson’s, they are being explored because both diseases involve impaired insulin signaling and energy metabolism in the brain.

These peptides improve neuronal insulin sensitivity, reduce inflammation, and enhance synaptic connections. Preclinical studies show reduced amyloid and tau buildup, and early Parkinson’s trials suggest lasting motor improvements. Clinical trials are ongoing.

Elamipretide (SS-31)

Elamipretide is a mitochondria-targeted tetrapeptide that binds cardiolipin, a lipid critical for mitochondrial structure. By stabilizing mitochondria, it reduces oxidative stress, prevents fragmentation, and supports energy production.

In Parkinson’s models, Elamipretide protected dopamine neurons and maintained motor function. In Alzheimer’s models, it lowered amyloid accumulation and improved synaptic activity. It has been studied in humans for other conditions but not yet in AD or PD.

α-Synuclein–Directed Approaches

α-Synuclein aggregation is central to Parkinson’s pathology. NPT200-11, though not a peptide, is a small molecule that prevents α-synuclein misfolding and has shown benefits in preclinical studies and early clinical testing.

Peptide-based methods, such as Tat-βsyn-degron, are designed to tag α-synuclein for clearance by the proteasome. In rodent models, this reduced toxic protein buildup and preserved motor function, highlighting the promise of direct protein-targeted strategies.

P110 (Mitochondrial Dynamics Modulator)

P110 is a short peptide that prevents excessive mitochondrial fragmentation by blocking abnormal Drp1 activity. Maintaining intact mitochondrial networks helps neurons resist oxidative stress and energy failure.

Studies show P110 preserves neuronal survival in Alzheimer’s, Parkinson’s, and ALS models. Although primarily a laboratory tool, it demonstrates the therapeutic potential of targeting mitochondrial health.

Selank (Tuftsin-Derived Peptide)

Selank is a synthetic peptide derived from tuftsin, initially developed as an anti-anxiety therapy. It reduces stress responses via GABA modulation and enhances cognitive function.

Preclinical studies show Selank increases brain-derived neurotrophic factor (BDNF), lowers inflammatory cytokines, and protects against alcohol-related memory deficits. Though not yet evaluated in large Alzheimer’s or Parkinson’s trials, it illustrates how peptides can broadly enhance resilience.

CN-105 (APOE-Mimetic Peptide)

CN-105 is a 5–amino acid peptide based on APOE, a gene that significantly influences Alzheimer’s risk. Designed to mimic protective APOE functions in a brain-penetrant form, CN-105 has shown promise in animal models.

It reduces amyloid accumulation, dampens neuroinflammation, and improves cognition. A Phase I clinical trial confirmed its safety and ability to reach the central nervous system, supporting further research.

RD2 and Amyloid-Clearing Peptides

RD2 is made of D-amino acids, which make it resistant to enzymatic degradation. It binds toxic amyloid-beta oligomers and prevents them from aggregating.

In advanced Alzheimer’s mouse models, RD2 reversed memory decline and reduced amyloid pathology. Earlier versions, such as D3, showed similar activity. RD2 has progressed to early human trials, representing a novel approach to directly clearing harmful protein aggregates.

Future Directions and Research Needs

• CRISPR-enabled peptide discovery: Gene editing is accelerating the identification of protective peptides and may one day enable therapeutic expression directly in patients.
• Intranasal delivery: Nasal sprays provide a non-invasive route for delivering peptides into the brain.
• Hybrid peptides: Multifunctional chimeras—such as combined Humanin and SS-31 (HNSS)—are being developed to target multiple disease pathways simultaneously.

Conclusion

Peptides represent a new frontier in the treatment of Alzheimer’s and Parkinson’s. Their ability to reach the brain, engage natural defense mechanisms, and address multiple aspects of disease makes them uniquely suited to tackling complex neurodegeneration.

While most remain in preclinical or early clinical stages, findings from laboratory studies and initial trials highlight their promise. Peptides such as Davunetide, Humanin, Elamipretide, and GLP-1 analogues could shape the future of disease-modifying therapies for neurodegenerative disorders.

Product available for research use only:

 

Sources

• Gozes I. et al., “Unexpected gender differences in progressive supranuclear palsy reveal efficacy for davunetide in women,” Translational Psychiatry, 2023.
• Karachaliou C-E. & Livaniou E., “Neuroprotective Action of Humanin and Humanin Analogues: Research Findings and Perspectives,” Biology (Basel), 2023.
• Kim K.H. et al., “Intranasal delivery of mitochondrial protein humanin rescues cell death and promotes mitochondrial function in Parkinson’s disease,” Theranostics, 2023.
• Kong F. et al., “GLP-1 receptor agonists in experimental Alzheimer’s disease models: a systematic review and meta-analysis of preclinical studies,” Front. Pharmacol., 2023.
• Lv D. et al., “Neuroprotective effects of GLP-1 class drugs in Parkinson’s disease,” Front. Neurology, 2024.
• Nguyen T.N. et al., “Neuroprotective Effects of a Small Mitochondrially-Targeted Tetrapeptide Elamipretide in Neurodegeneration,” Front. Integr. Neurosci., 2022.
• Price D.L. et al., “The small molecule α-synuclein misfolding inhibitor, NPT200-11, produces multiple benefits in an animal model of Parkinson’s disease,” Scientific Reports, 2018, 8:16165.
• Jin J.W. et al., “Development of an α-synuclein knockdown peptide and evaluation of its efficacy in Parkinson’s disease models,” Communications Biology, 2021.
• Rios L. et al., “Targeting an allosteric site in Drp1 to inhibit Fis1-mediated mitochondrial dysfunction,” Nature Communications, 2023.
• Kolik L.G. et al., “Selank, peptide analogue of tuftsin, protects against ethanol-induced memory impairment by regulation of BDNF in rat brain,” Bull. Exp. Biol. Med., 2019.
• Krishnamurthy K. et al., “ApoE mimetic peptide CN-105 reduces pathology and improves behavior in a model of Alzheimer’s disease,” Brain Research, 2020.
• Schemmert S. et al., “Aβ oligomer elimination restores cognition in transgenic Alzheimer’s mice with full-blown pathology,” Mol. Neurobiol., 2019.
• Qian K. et al., “SS31/S14G-Humanin hybrid peptide with amplified multimodal efficacy and bio-permeability for the treatment of Alzheimer’s disease,” Asian J. Pharm. Sci., 2024.